The Chandler, Arizona-based company said it had net income of 10 cents per share. Earnings, adjusted for stock option expense and pretax expenses, came to 21 cents per share.

The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 23 cents per share.

The specialty pharmaceutical company posted revenue of $77.6 million in the period.

Insys Therapeutics shares have more than doubled since the beginning of the year. The stock has more than tripled in the last 12 months.